Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03953157|
Recruitment Status : Recruiting
First Posted : May 16, 2019
Last Update Posted : June 27, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Arthralgia Postmenopausal Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8||Dietary Supplement: Dietary Intervention Behavioral: Exercise Intervention Other: Questionnaire Administration||Not Applicable|
I. To recruit an ethnically, racially and culturally diverse sample of postmenopausal women diagnosed with estrogen receptor positive breast cancer who are currently taking aromatase inhibitor (AI), establish eligibility, and randomly allocate 20 participants to a two-arm parallel intervention trial.
II. Conduct baseline measurements of: body composition and bone mineral density, reported muscle and joint pain; inflammatory, cardiovascular and bone health markers contained in blood serum; and, cardiovascular function.
III. Conduct a three month anti-inflammatory dietary intervention in one arm, and bone strengthening exercise intervention in the other study arm.
IV. At completion of these 3-month interventions, evaluate changes since baseline of body composition, bone density, reported muscle and joint pain, and inflammatory and cardiovascular measurements within each intervention arm, and preliminarily contrast changes between intervention arms.
V. Utilize results from both intervention arms to design a larger 2x2 randomized factorial trial designed to assess effects of anti-inflammatory diet, effects of bone promoting exercise, and combined diet and exercise intervention effects on joint and muscle pain, inflammatory markers, bone mineral density, and cardiovascular measures.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive a controlled anti-inflammatory diet over 12 weeks.
ARM II: Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
After completion of study, patients are followed up at 1 week.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Improving Health of Women on Aromatase Inhibitors|
|Actual Study Start Date :||October 7, 2019|
|Estimated Primary Completion Date :||June 1, 2023|
|Estimated Study Completion Date :||June 1, 2024|
Experimental: Arm I (dietary intervention)
Patients receive a controlled anti-inflammatory diet over 12 weeks.
Dietary Supplement: Dietary Intervention
Receive dietary intervention
Other: Questionnaire Administration
Experimental: Arm II (exercise intervention)
Patients undergo controlled exercise sessions with a dedicated trainer 3 times a week for up to 1 hour each over 12 weeks.
Behavioral: Exercise Intervention
Receive exercise intervention
Other: Questionnaire Administration
- Bone mineral density [ Time Frame: Baseline up to 1 week post intervention ]Will be scanned by dual x-ray absorptiometry (iDXA).
- Joint and muscle pain [ Time Frame: Baseline up to 1 week post intervention ]Joint and muscle pain will be measured by the Brief Pain Inventory, a frequently administered assessment for studies of women on aromatase inhibitors (AIs). Participants will be asked about use of pain medication and supplements such as chondroitin and glucosamine. Subjects will also fill out standard visual analog scales to rate intensity of pain ranging from 1 to 10, as well as locate source of pain on standardized human figures available from International Society of Anesthetic Pharmacology. Additionally grip strength, a common marker of functional muscle and joint weakness, will be assessed using a dynamometer.
- Inflammatory markers [ Time Frame: Baseline up to 1 week post intervention ]Fasting blood samples will be collected at baseline and end of intervention. Serum markers, IL-6, Il-8, TNF-?, MCP-1, hs-CRP, leptin, TGFbeta, IL-1beta, and CRP will be quantified.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- At least 6 months since breast cancer diagnosis up to 2 years since diagnosis.
- Diagnosed with localized breast cancer, up to stage IIIa.
- Has been taking aromatase inhibitor (AIs) for at least six months.
- Has been experiencing mild to moderate arthralgia (joint pain) for at least 2 months determined by the Brief Pain Inventory (BPI).
- At least 6 months post chemotherapy or radiation treatment.
- Subjects must be in good health as determined by medical history, physical examination, iDXA scan and clinical laboratory measurements.
- Postmenopausal either natural or surgical or postmenopausal caused by ovarian suppression treatments administered to premenopausal women.
- Currently taking aromatase inhibitor medication.
- Diagnosed with metastatic breast cancer.
- Currently undergoing chemotherapy or radiation treatment.
- Food allergies of any kind, or any medical condition requiring mandatory dietary restrictions.
- A bone mineral density (BMD) T score less than -1, or fracture since taking AIs, or current use of glucocorticoids.
- Taking bisphosphonates or any other medication for bone loss.
- Significant cardiac, pulmonary, renal, liver or psychiatric disease.
- Currently undergoing or engaging in a regular exercise program.
- Muscular, orthopedic, or cardiovascular limitations that would prevent full participation in exercise.
- Body mass index (BMI) greater than 40 kg/m^2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03953157
|Contact: Gail Thamesfirstname.lastname@example.org|
|United States, California|
|UCLA / Jonsson Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Gail Thames 310-825-0453 email@example.com|
|Contact: Catherine L. Carpenter, PhD 310-825-8499 firstname.lastname@example.org|
|Principal Investigator: Catherine L. Carpenter, PhD|
|Principal Investigator:||Catherine L Carpenter||UCLA / Jonsson Comprehensive Cancer Center|
|Responsible Party:||Jonsson Comprehensive Cancer Center|
|Other Study ID Numbers:||
NCI-2019-02909 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
18-001926 ( Other Identifier: UCLA / Jonsson Comprehensive Cancer Center )
|First Posted:||May 16, 2019 Key Record Dates|
|Last Update Posted:||June 27, 2022|
|Last Verified:||May 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
Neoplasms by Site